Heyworth M F
Immunol Rev. 1982;65:79-97. doi: 10.1111/j.1600-065x.1982.tb00428.x.
Many different antilymphocytic antisera have been used clinically, and the properties of any particular type of ALS are not necessarily identical to those of any other type. Nevertheless, it is possible to draw certain general conclusions about the effects of ALS in human subjects. ALS administration has often been shown to reduce the number of circulating E-rosette-positive lymphocytes, although the precise mechanisms by which this reduction occurs are not known. Using a combined technique of E-rosette formation and immunofluorescence, heterologous immunoglobulin has been demonstrated on T and non-T lymphocytes from patients receiving non-selective ALS. Fifteen years' experience has failed to provide convincing support for the view that ALS (including immunoglobulin prepared from the whole antiserum) prolongs human renal allograft survival. It is not yet known whether ALS is a useful immunosuppressive agent in cardiac transplantation. One observation of possible clinical interest is that bone marrow regeneration has occurred in a number of patients with aplastic anemia who have been treated with ALS. No satisfactory method has been developed for monitoring the dose of ALS in human subjects. Appropriate studies may determine whether monoclonal antilymphocytic antibodies are clinically useful, for example in prolonging the survival of transplanted organs, in preventing or treating graft-versus-host disease, or in treating lymphoma, leukemia, or aplastic anemia.
临床上已使用了多种不同的抗淋巴细胞抗血清，任何一种特定类型的抗淋巴细胞血清的特性不一定与其他类型的相同。然而，对于抗淋巴细胞血清在人体中的作用，可以得出某些一般性结论。经常显示给予抗淋巴细胞血清会减少循环中E玫瑰花结阳性淋巴细胞的数量，尽管这种减少发生的确切机制尚不清楚。使用E玫瑰花结形成和免疫荧光的联合技术，已在接受非选择性抗淋巴细胞血清的患者的T淋巴细胞和非T淋巴细胞上证实了异源免疫球蛋白的存在。十五年的经验未能为抗淋巴细胞血清（包括从全抗血清制备的免疫球蛋白）能延长人类肾移植存活时间这一观点提供令人信服的支持。目前尚不清楚抗淋巴细胞血清在心脏移植中是否是一种有用的免疫抑制剂。一个可能具有临床意义的观察结果是，一些接受抗淋巴细胞血清治疗的再生障碍性贫血患者出现了骨髓再生。尚未开发出用于监测人体中抗淋巴细胞血清剂量的满意方法。适当的研究可能会确定单克隆抗淋巴细胞抗体在临床上是否有用，例如在延长移植器官的存活时间、预防或治疗移植物抗宿主病，或治疗淋巴瘤、白血病或再生障碍性贫血方面。
